### 2.2.1	In vitro / physicochemical Data

A literature search was performed to collect available information on physicochemical properties of carbamazepine and carbamazepine-10,11-epoxide. The information is summarized in the table below. 

| **Parameter**   | **Unit** | **Value**       | Source                                                       | **Description**                                 |
| :-------------- | -------- | --------------- | ------------------------------------------------------------ | ----------------------------------------------- |
| **Carbamazepine** |  |  |  |  |
| MW              | g/mol    | 236.27    | [DrugBank DB00564](#5-References) | Molecular weight                                |
| logP (calculated)                        |                          | 1.54                                   | [Austin 2002](#5-References)      | Partition coefficient between octanol and water         |
| logP (calculated)                        |                          | 2.1                                    | [DrugBank DB00564](#5-References) | Partition coefficient between octanol and water         |
| logP (calculated)                        |                          | 2.77                                   | [DrugBank DB00564](#5-References) | Partition coefficient between octanol and water         |
| Solubility (pH) | µg/mL   | 336 (6.2)                              | [Annaert 2010](#5-References) | Solubility in human intestinal fluid |
| Solubility (pH) | µg/mL | 283 (7.0)                              | [Söderlind 2010](#5-References) | Solubility in human intestinal fluid |
| Solubility (pH) | µg/mL                    | 306 (6.9)                              | [Clarysse 2011](#5-References)    | Solubility in fasted human intestinal fluid             |
| f<sub>u</sub>                            |                          | 0.25                                   | [Pynnönen 1977](#5-References)    | Fraction unbound in plasma of healthy subjects          |
| f<sub>u</sub> | | 0.243 ± 0.013 [0.225 - 0.258]<sup>a</sup> | [Morselli 1975](#5-References) | Fraction unbound in plasma of healthy male subjects |
| f<sub>u</sub>                            |                          | 0.239                                  | [Di Salle 1974](#5-References)    | Fraction unbound in plasma of normal subjects           |
| f<sub>u</sub> | | 0.237 ± 0.031<sup>b</sup> | [Vinçon 1987](#5-References) | Fraction unbound in plasma of epileptic patients |
| f<sub>u</sub>                            |                          | 0.182 ± 0.05 [0.103 - 0.297]<sup>a</sup> | [Hooper 1975](#5-References)      | Fraction unbound in plasma of normal subjects           |
| K<sub>m</sub> CYP2B6                     | µM                       | 420                                    | [Pearce 2002](#5-References)      | CYP2B6 Michaelis-Menten constant                        |
| V<sub>max</sub> CYP2B6 | pmol/min/pmol rec enzyme | 0.429                                  | [Pearce 2002](#5-References)      | in vitro metabolic rate constant for recombinant CYP2B6 |
| K<sub>m</sub> CYP2C8 | µM                       | 757                                    | [Cazali 2003](#5-References)      | CYP2C8 Michaelis-Menten constant                        |
| V<sub>max</sub> CYP2C8 | pmol/min/pmol rec enzyme | 0.673                                  | [Cazali 2003](#5-References)      | in vitro metabolic rate constant for recombinant CYP2C8 |
| K<sub>m</sub> CYP3A4<sup>c</sup> | µM                       | 282                                    | [Pearce 2002](#5-References)      | CYP3A4 Michaelis-Menten constant                        |
| K<sub>m</sub> CYP3A4 (→CBZE)<sup>d</sup> | µM                       | 248                                    | [Huang 2004](#5-References)       | CYP3A4 Michaelis-Menten constant                        |
| K<sub>m</sub> UGT2B7 | µM                       | 214                                    | [Staines 2004](#5-References)     | UGT2B7 Michaelis-Menten constant                        |
| V<sub>max</sub> UGT2B7 | pmol/min/mg mic enzyme   | 0.79                                   | [Staines 2004](#5-References)     | in vitro metabolic rate constant for microsomal enzymes |
| Microsomal UGT2B7 | pmol/mg mic protein      | 82.9                                   | [Achour 2014](#5-References)      | Content of UGT2B7 proteins in liver microsomes          |
| Intestinal permeability                  | cm/min                   | 0.0258                                 | [Lennernäs 2007](#5-References) | Transcellular intestinal permeability        |
| **Carbamazepine-10,11-epoxide** |  |  |  |  |
| MW | g/mol | 252.27 | [DrugBank DBMET00291](#5-References) | Molecular weight |
| logP (calculated) |  | 1.58 | [DrugBank DBMET00291](#5-References) | Partition coefficient between octanol and water |
| logP (calculated) |  | 1.97 | [DrugBank DBMET00291](#5-References) | Partition coefficient between octanol and water |
| Solubility (pH) | µg/mL | 1340 (7.0) | [DrugBank DBMET00291](#5-References) | Solubility |
| f<sub>u</sub> |  | 0.489 ± 0.021 [0.468 - 0.518]<sup>a</sup> | [Morselli 1975](#5-References) | Fraction unbound in plasma of healthy male subjects |
| f<sub>u</sub> | | 0.491 ± 0.042<sup>b</sup> | [Vinçon 1987](#5-References) | Fraction unbound in plasma of epileptic patients |
<sup>a</sup> denotes mean ± standard deviation [range]

<sup>b</sup> denotes mean ± standard deviation

<sup>c</sup> refers to CYP3A4-mediated reaction forming other metabolites than carbamazepine-10,11-epoxide

<sup>d</sup> refers to CYP3A4-mediated reaction forming carbamazepine-10,11-epoxide


### 2.2.2	Clinical Data

A literature search was performed to collect available clinical data on carbamazepine and carbamazepine-10,11-epoxide in healthy adult subjects.

The following studies were used for model building and evaluation:

| Publication                                                 | Arm / Treatment / Information used for model building        |
| :---------------------------------------------------------- | :----------------------------------------------------------- |
| [Barzaghi 1987](#5-References)                              | Healthy subjects receiving a single oral dose of 400 mg carbamazepine |
| [Bedada 2015](#5-References)                                | Healthy subjects receiving a single oral dose of 200 mg carbamazepine |
| [Bedada 2016](#5-References)                                | Healthy subjects receiving a single oral dose of 200 mg carbamazepine |
| [Bernus 1994](#5-References)                                | Healthy subjects receiving two oral doses of 600 mg carbamazepine |
| [Bianchetti 1987](#5-References)                            | Healthy subjects receiving a single oral dose of 400 mg carbamazepine |
| [Burstein 2000](#5-References)                              | Healthy subjects receiving a multiple oral doses of carbamazepine, starting at 100 mg and escalating to 400 mg |
| [Caraco 1995](#5-References)                                | Healthy lean subjects receiving a single oral dose of 200 mg carbamazepine |
| [Caraco 1995](#5-References)                                | Obese but otherwise healthy subjects receiving a single oral dose of 200 mg carbamazepine |
| [Cawello 2000](#5-References)                               | Healthy subjects receiving a multiple oral doses of carbamazepine, starting at 100 mg and escalating to 200 mg |
| [Cotter 1977](#5-References)                                | Healthy subject receiving a single oral dose of 800 mg carbamazepine |
| [Dalton 1985a](#5-References)                               | Healthy subjects receiving a single oral dose of 600 mg carbamazepine |
| [Dalton 1985b](#5-References)                               | Healthy subjects receiving a single oral dose of 600 mg carbamazepine |
| [Eichelbaum 1985](#5-References)                            | Healthy subjects receiving a single oral dose of 200 mg carbamazepine |
| [Elqidra 2004](#5-References)                               | Healthy subjects receiving a single oral dose of 200 mg carbamazepine |
| [European Patent Application EP 1044681 A2](#5-References)  | Healthy subjects receiving a single oral dose of 400 and 600 mg carbamazepine |
| [Gérardin 1976](#5-References)                              | Healthy subjects receiving a single oral dose of 100, 200, and 600 mg carbamazepine |
| [Gérardin 1990](#5-References)                              | Healthy subjects receiving a single oral dose of 100 mg carbamazepine concomitantly with a single intravenous dose of 10 mg carbamazepine |
| [Ji 2008](#5-References)                                    | Healthy subjects receiving a multiple oral doses of carbamazepine, starting at 200 mg and escalating to 400 mg |
| [Kayali 1994](#5-References)                                | Healthy subjects receiving a single oral dose of 200 mg carbamazepine |
| [Kim 2005](#5-References)                                   | Healthy subjects receiving a single oral dose of 200 mg carbamazepine |
| [Kovacević 2009](#5-References)                             | Healthy subjects receiving a single oral dose of 400 mg carbamazepine |
| [Levy 1975](#5-References)                                  | Healthy subjects receiving a single oral carbamazepine dose of 6 mg/kg body weight |
| [McLean 2001](#5-References)                                | Healthy subjects receiving a single oral dose of 400 mg carbamazepine |
| [Meyer 1996](#5-References)                                 | Healthy subjects receiving a single oral dose of 200 mg carbamazepine |
| [Meyer 1998](#5-References)                                 | Healthy subjects receiving a single oral dose of 200 mg carbamazepine |
| [Miles 1989](#5-References)                                 | Healthy subjects receiving a multiple oral doses of 300 and 400 mg carbamazepine |
| [Møller 2001](#5-References)                                | Healthy subjects receiving a multiple oral doses of carbamazepine, starting at 100 mg and escalating to 400 mg |
| [Morselli 1975](#5-References)                              | Healthy subjects receiving a single oral dose of 400 mg carbamazepine |
| [Pisani 1988](#5-References)                                | Healthy subjects receiving a single oral dose of 100 mg carbamazepine-10,11-epoxide |
| [Pisani 1990](#5-References)                                | Healthy subjects receiving a single oral dose of 100 mg carbamazepine-10,11-epoxide |
| [Pisani 1992](#5-References)                                | Healthy subjects receiving a single oral dose of 100 mg carbamazepine-10,11-epoxide |
| [Pynnönen 1977](#5-References)                              | Healthy subjects receiving a single oral dose of 400 mg carbamazepine |
| [Rawlins 1975](#5-References)                               | Healthy subject receiving a single oral dose of 50, 100, and 200 mg carbamazepine |
| [Saint-Salvi 1987](#5-References)                           | Healthy subjects receiving a single oral dose of 200 mg carbamazepine |
| [Stevens 1998](#5-References)                               | Healthy subjects receiving multiple oral doses of 400 mg carbamazepine |
| [Strandjord 1975](#5-References)                            | Healthy subjects receiving a single oral dose of 400 mg carbamazepine |
| [Sumi 1987](#5-References)                                  | Healthy subjects receiving single oral doses of 200 mg carbamazepine and of 150 mg carbamazepine-10,11-epoxide |
| [Tomson 1983](#5-References)                                | Healthy subjects receiving single oral doses of 200 mg carbamazepine and of 50, 100, and 200 mg carbamazepine-10,11-epoxide |
| [US Patent Application - US 2009/0169619 A1](#5-References) | Healthy subjects receiving a single oral dose of 300 mg carbamazepine |
| [US Patent Application - US 2014/0302138 A1](#5-References) | Healthy subjects receiving a single oral dose of 400 mg carbamazepine |
| [Wada 1978](#5-References)                                  | Healthy subjects receiving a single oral dose of 200 mg carbamazepine |
| [Wong 1983](#5-References)                                  | Healthy subjects receiving a single oral dose of 400 mg carbamazepine |

